First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors

Authors: Kohei Shitara, Satoshi Ueha, Shigeyuki Shichino, Hiroyasu Aoki, Haru Ogiwara, Tetsuya Nakatsura, Toshihiro Suzuki, Manami Shimomura, Toshiaki Yoshikawa, Kayoko Shoda, Shigehisa Kitano, Makiko Yamashita, Takayuki Nakayama, Akihiro Sato, Sakiko Kuroda, Masashi Wakabayashi, Shogo Nomura, Shoji Yokochi, Satoru Ito, Kouji Matsushima, Toshihiko Doi

Source: Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)

Subject Terms: Anti-CD4 antibody, CD4+ T cells, CD8+ T cells, Immunotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://link.springer.com/article/10.1186/s40425-019-0677-y; https://doaj.org/toc/2051-1426

Access URL: https://doaj.org/article/f3fa5960399a4030b38ca80859495c2b

Enhancement of antitumor effect by peptide vaccine therapy in combination with anti-CD4 antibody: Study in a murine model

Authors: Norihiro Fujinami, Toshiaki Yoshikawa, Yu Sawada, Manami Shimomura, Tatsuaki Iwama, Shiori Sugai, Shigehisa Kitano, Yasushi Uemura, Tetsuya Nakatsura

Source: Biochemistry and Biophysics Reports, Vol 5, Iss C, Pp 482-491 (2016)

Subject Terms: Cancer, Immunotherapy, Peptide vaccine, Anti-CD4 antibody, Murine liver metastatic model, Biology (General), QH301-705.5, Biochemistry, QD415-436

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2405580816300164; https://doaj.org/toc/2405-5808

Access URL: https://doaj.org/article/abe1098a9e3e4ddebc235da700710c18

Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors

Authors: Nobuhiro Tsuchiya, Ako Hosono, Toshiaki Yoshikawa, Kayoko Shoda, Kazuto Nosaka, Manami Shimomura, Junichi Hara, Chika Nitani, Atsushi Manabe, Hiroki Yoshihara, Yosuke Hosoya, Hide Kaneda, Yoshiaki Kinoshita, Kenichi Kohashi, Kenichi Yoshimura, Norihiro Fujinami, Keigo Saito, Shoichi Mizuno, Tetsuya Nakatsura

Source: OncoImmunology, Vol 7, Iss 1 (2018)

Subject Terms: peptide vaccine, glypican-3 (gpc3), ctl, pediatric solid tumors, phase i, Immunologic diseases. Allergy, RC581-607, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2162-402X

Access URL: https://doaj.org/article/5f76819309494872a07ab5ff75f4dada

Organoids with cancer stem cell-like properties secrete exosomes and HSP90 in a 3D nanoenvironment.

Authors: Takanori Eguchi, Chiharu Sogawa, Yuka Okusha, Kenta Uchibe, Ryosuke Iinuma, Kisho Ono, Keisuke Nakano, Jun Murakami, Manabu Itoh, Kazuya Arai, Toshifumi Fujiwara, Yuri Namba, Yoshiki Murata, Kazumi Ohyama, Manami Shimomura, Hirohiko Okamura, Masaharu Takigawa, Tetsuya Nakatsura, Ken-Ichi Kozaki, Kuniaki Okamoto, Stuart K Calderwood

Source: PLoS ONE, Vol 13, Iss 2, p e0191109 (2018)

Subject Terms: Medicine, Science

File Description: electronic resource

Relation: http://europepmc.org/articles/PMC5802492?pdf=render; https://doaj.org/toc/1932-6203

Access URL: https://doaj.org/article/921dd99a06f24871ae74dcd1bd37fa52

Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate.

Authors: SHIORI SUGAI, TOSHIAKI YOSHIKAWA, TATSUAKI IWAMA, NOBUHIRO TSUCHIYA, NORIHIRO UEDA, NORIHIRO FUJINAMI, MANAMI SHIMOMURA, RONG ZHANG, SHIN KANEKO, YASUSHI UEMURA, TETSUYA NAKATSURA

Source: International Journal of Oncology; May2016, Vol. 48 Issue 5, p1794-1804, 11p

Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes.

Authors: YU SAWADA, TOSHIAKI YOSHIKAWA, MANAMI SHIMOMURA, TATSUAKI IWAMA, ITARU ENDO, TETSUYA NAKATSURA

Source: International Journal of Oncology; 2015, Vol. 46 Issue 1, p28-36, 9p